Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2021-08-26 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于2021年半年度主要经营数据的公告.doc
Interim / Quarterly Report Classification · 95% confidence The document is titled as an announcement regarding the company's 2021 half-year main operating data. It contains detailed financial data for the first half of 2021, including revenue, net profit, cash flow, assets, and business segment breakdowns. It also includes operational data such as store expansion and insurance qualification status. The document length is 2919 characters, which is relatively short but contains substantive financial and operational data rather than just a notice or link to a report. The content corresponds to a half-year comprehensive financial report with actual financial figures and analysis, fitting the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-26 Chinese
益丰药房关于归还部分暂时用于补充流动资金的可转换公司债券募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the repayment of part of the funds raised through convertible bonds that were temporarily used to supplement working capital. It details the amount repaid, references previous announcements about the use of these funds, and states the company's commitment to disclose further information. The content focuses on capital usage and repayment, which aligns with updates on financing activities or capital structure changes. The document is relatively short (832 characters) and is not a full financial report or audit. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-08-03 Chinese
湖南启元律师事务所关于益丰大药房连锁股份有限公司2019年限制性股票激励计划预留授予的限制性股票第一期解锁暨上市的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the unlocking and listing of restricted shares under a 2019 restricted stock incentive plan of a company. It details the approval process, conditions for unlocking, performance assessments, and stock structure changes related to the stock incentive plan. It is not a financial report, earnings release, or management discussion, but a legal opinion on a specific corporate action related to stock incentives. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal filing related to corporate governance and stock incentive plans, not a standalone audit report or annual report or a direct announcement of voting results or capital changes. The document length and content confirm it is not a brief announcement but a detailed legal opinion letter, fitting RNS rather than RPA or other categories.
2021-07-05 Chinese
益丰药房关于注销部分非公开发行募集资金专项账户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation of certain special accounts for raised funds (募集资金专项账户) related to non-public issuance and convertible bonds. It details the background of the fundraising, the management and use of the funds, and the specific bank accounts being closed after the funds have been fully used. The document includes references to regulatory approvals and verification reports but does not contain financial statements or detailed financial performance data. It is a formal disclosure about the status and management of fundraising accounts, which fits the category of Capital/Financing Update (CAP) as it relates to the company's fundraising activities and capital management.
2021-07-05 Chinese
益丰药房关于2019年限制性股票激励计划预留授予的限制性股票第一期解锁暨上市的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the unlocking and listing of restricted shares under a 2019 restricted stock incentive plan. It details the number of shares unlocked, the dates of unlocking, the conditions met for unlocking, and the legal and supervisory opinions on the matter. It is focused on share-based compensation and stock unlocking events rather than financial results, management changes, or regulatory filings. This type of announcement fits best under the category of Transaction in Own Shares (POS), as it reports on the company's own shares being unlocked and becoming tradable, which is a form of share transaction by the company.
2021-07-05 Chinese
中信证券股份有限公司关于益丰大药房连锁股份有限公司使用可转换公司债券部分闲置募集资金暂时补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of idle raised funds from a convertible bond issuance by Yifeng Pharmacy Chain Co., Ltd. It includes specifics about the bond issuance, fund allocation, internal decision procedures, and compliance with regulatory requirements. The content focuses on the use of funds and regulatory compliance rather than presenting financial statements or audit results. It is not an annual or interim report, audit report, or earnings release. The document is a formal verification or opinion related to regulatory compliance and fund usage, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update or Audit Report. The document length is under 5,000 characters and is a formal opinion rather than a report itself, so it is not a Report Publication Announcement (RPA).
2021-06-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.